Research map: Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review

Back to the article

Papers in this map

  1. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews · Matthew James Page · 2021 · 106363 citations · Cited by this paper
  2. Trans-Presentation of IL-15 by IL15Rα Attenuates Tumor Immune Surveillance and Is Dispensable for IL-15-Dependent Tumor Growth Control · 2026 · Related
  3. Hallmarks of Cancer: The Next Generation · Douglas Hanahan · 2011 · 67934 citations · Cited by this paper
  4. Survivorship Challenges in Metastatic Prostate Cancer in the Era of Prolonged Survival: A Review · 2026 · Related
  5. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors · Richard L. Wahl · 2009 · 3834 citations · Cited by this paper
  6. Factors Associated with the Timing of Liver Metastasis After Colorectal Cancer Surgery: A Retrospective Multicenter Study · 2026 · Related
  7. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors · Jonathan Strosberg · 2017 · 3312 citations · Cited by this paper
  8. Mapping Misconceptions in Neuroendocrine Tumor Nomenclature: A Scoping Review of National Database Studies and Clinical Implications · 2026 · Related
  9. Assessing Bias in Studies of Prognostic Factors · Jill Alison Hayden · 2013 · 3291 citations · Cited by this paper
  10. Interpreting Circulating Bile Acid Profiles in Pancreatic Cancer: The Role of Cholestasis and Its Management · 2026 · Related
  11. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer · Oliver A. Sartor · 2021 · 2844 citations · Cited by this paper
  12. Ex Vivo Line-Field Confocal Optical Coherence Tomography and Ex Vivo Fusion Confocal Microscopy for Lateral-Margin Assessment of Basal Cell Carcinoma in Correlation with Histopathology: A Prospective Pilot Diagnostic-Accuracy Study · 2026 · Related
  13. Partial-Volume Effect in PET Tumor Imaging · M. Soret · 2007 · 1566 citations · Cited by this paper
  14. Burden, Trends, and Future Projections of Multiple Myeloma in China from 1990 to 2023 · 2026 · Related
  15. Bystander killing effect of DS ‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity · Yusuke Ogitani · 2016 · 752 citations · Cited by this paper
  16. PTEN Protein Loss in Diagnostic Prostate Biopsies Is Associated with Gleason Score Upgrading in Radical Prostatectomy · 2026 · Related
  17. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial · Fernanda Mosele · 2023 · 394 citations · Cited by this paper
  18. Predictive Biomarkers of Systemic Therapy Response in Cutaneous Melanoma · 2026 · Related
  19. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer · Helen Lee · 2017 · 388 citations · Cited by this paper
  20. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial · Géraldine Gebhart · 2015 · 359 citations · Cited by this paper
  21. Repeatability of SUV in Oncologic 18F-FDG PET · Martin A. Lodge · 2017 · 225 citations · Cited by this paper
  22. A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy · Federico Riccardi · 2023 · 186 citations · Cited by this paper
  23. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody–Drug Conjugate Treatment · Laetitia E. Lamberts · 2015 · 103 citations · Cited by this paper
  24. PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET · Guus A.M.S. van Dongen · 2012 · 97 citations · Cited by this paper
  25. Immuno-PET for Clinical Theranostic Approaches · Clément Bailly · 2016 · 77 citations · Cited by this paper
  26. Designing the Magic Bullet? The Advancement of Immuno-PET into Clinical Use · Brian D. Wright · 2013 · 71 citations · Cited by this paper
  27. Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody · Jorge A. Carrasquillo · 2019 · 68 citations · Cited by this paper
  28. Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT · Dan Sandberg · 2017 · 60 citations · Cited by this paper
  29. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial) · Magdalena Mileva · 2024 · 53 citations · Cited by this paper
  30. Human Epidermal Growth Factor Receptor 2–Targeting [ 68 Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer · Ali Alhuseinalkhudhur · 2023 · 50 citations · Cited by this paper
  31. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy · Florian Rosar · 2021 · 46 citations · Cited by this paper
  32. The predictive value of pretherapy [68Ga]Ga-DOTA-TATE PET and biomarkers in [177Lu]Lu-PRRT tumor dosimetry · Azadeh Akhavanallaf · 2023 · 41 citations · Cited by this paper
  33. Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial · Shanu Modi · 2025 · 39 citations · Cited by this paper
  34. Use of 64 Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine for Metastatic Breast Cancer: A Pilot Study · Joanne E. Mortimer · 2021 · 38 citations · Cited by this paper
  35. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [ 68 Ga]Ga-ABY-025: Results from a Pilot Study · Renske Altena · 2024 · 34 citations · Cited by this paper
  36. Advances and challenges in immunoPET methodology · Philipp Mohr · 2024 · 32 citations · Cited by this paper
  37. Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications · Renske Altena · 2023 · 26 citations · Cited by this paper
  38. Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial · Jens‐Uwe Blohmer · 2010 · 22 citations · Cited by this paper
  39. Landscape of clinical drug development of ADCs used for the pharmacotherapy of cancers: an overview of clinical trial registry data from 2002 to 2022 · Wenjing Zhou · 2024 · 22 citations · Cited by this paper

Source: OpenAlex (CC0)